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Atrial septal defect (ASD) is the most frequently diagnosed conge-
nital heart disease in adulthood. Along with the recent evolvement 
of therapeutic catheterization, transcatheter closure has become the 
treatment of choice in most secundum type ASDs in children and ad-
ults. However, clinical decision and technical details may be influ-
enced by special circumstances including complex morphology of 
the defect, co-morbid disease, significant arrhythmia, pulmonary ar-
terial hypertension (PAH), tricuspid or mitral insufficiency, ventric-
ular dysfunction, and age of the patient, especially in very young or 
elderly patients. Pathophysiology in elderly patients with hemodyna-
mically significant ASD shows the nature of the problems to be very 
complex; such problems are frequently combined and usually inter-
acted negatively. Nevertheless, transcatheter ASD closure may be po-
tentially subtracted from the treatment option because the risk-be-
nefit relationship of the procedure has been less-clearly defined in 
this age group.1) 
In this issue, the article by Woo et al.2) reported the safety and ef-
ficacy of the transcatheter closure of ASD in elderly patients. In spite 
of the small cohort of patients, this study also demonstrated the 
substantial risk and complications frequently encountered in elder-
ly patients with ASD. All of their patients who successfully under-
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went device closure except for 1 fatal case, showed improvement of 
functional status or were in New York Heart Association functional 
class I, along with the favorable geometric reverse remodeling of 
the heart on the follow-up evaluation. PAH was detected in 65.2% 
of their cohort including 3 patients with mean pulmonary arterial 
pressure exceeding 40 mm Hg (peak systolic pressures were not de-
scribed), while fenestration of the device was not performed in any 
of the patients. The use of a self-fabricated fenestrated device has 
been reported to reduce post-procedural risk either in patients with 
severe PAH or in elderly patients at the risk of masked left ventricu-
lar (LV) restriction.1)3)4) The indications for implanting a fenestrated 
device in patients with PAH are not yet clearly defined, whereas many 
interventionists consider using a fenestrated device in patients with 
severe PAH (usually defined as peak systolic pulmonary arterial pres-
sure ≥60 mm Hg). A “masked LV restriction” is suspected when se-
rious pulmonary edema secondary to LV dysfunction and increase in 
left atrium (LA) pressure develop after ASD closure,5) and may appear 
in 2% to 3.6% of elderly patients.6-8) The pathogenetic mechanism 
may be explained by chronic compression of LV due to the dilated 
right ventricle which reduces the LV end-diastolic volume in a chron-
ic setting. The authors postulated that the death of one patient might 
have been caused by acute LV dysfunction which may correspond 
to the masked LV restriction. Unfortunately, they failed to screen this 
patient from current protocols for detection of masked LV restric-
tion. Another possibility is that the patient died due to a cause other 
than the masked LV restriction. They failed to enroll the patient as a 
candidate for a balloon occlusion test (BOT), because the patient 
showed relatively low LA pressure and LV end-diastolic pressure on 
the baseline hemodynamic study. There are 2 different protocols for 
detection and management of LV restriction, which have been in-
dependently described by 2 separate groups.5)7-9) Both protocols in-
clude temporary BOT with LA pressure measurement, whereas each 
protocol has many different criteria to define a significant LV rest-
riction.1) Despite their usefulness, these protocols are based on em-
pirical experiences rather than cumulated data which raises the need 
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for the development of a new evidence-based guideline from sub-
sequent large population based studies. In addition, BOT should be 
performed very carefully because several issues may be involved in 
the technical details of BOT including temporary obliteration of the 
pressure catheter tip, incomplete occlusion, as well as temporary 
restriction of the LA volume by a bulky, inflated balloon positioned 
inside the LA.
Another serious complication in this group of patients is arrhy-
thmia, most frequently atrial fibrillation followed by atrial flutter. 
There is a lack of data concerning the outcome of transcatheter ASD 
closure in elderly patients with chronic atrial arrhythmia. However, 
a study has revealed that transcatheter closure of ASD in elderly pa-
tients with permanent atrial fibrillation resulted in an improvement 
of functional status and reverse remodeling of the heart.10) A dra-
matic improvement in functional status in their patients indicates 
that volume overload is the key issue, rather than the atrial fibrilla-
tion, responsible for the poor functional performance in this pati-
ent group. Therefore, there has been a consensus that device closure 
with medical therapy (rate control) may be an attractive therapeutic 
option in elderly patients with chronic atrial fibrillation, especially in 
patients associated with high risk for surgery. Catheter ablation of 
atrial arrhythmia and device closure may also be a good option as the 
authors treated one of their patients this way.
As the authors demonstrated in their article, it is also very impor-
tant to detect and manage co-morbid systemic and cardiac diseases 
in the elderly ASD patient, not only because of the high prevalence 
of coincidental diseases in this age group, but also because the co-
morbid diseases may further complicate the procedure as well as 
negatively influence the outcome, and most importantly many of 
these adverse events could be prevented by adequate peri-proce-
dural management. 
Therefore, this report of the author’s initial experience implies 
the importance of a thorough and individualized evaluation fol-
lowed by a meticulous strategic approach for transcatheter ASD clo-
sure in elderly patients. Moreover, close follow-up as well as optimal 
treatment of residual and co-morbid diseases are imperative to en-
suring a good outcome after device closure; in addition, the patients 
should be fully informed about the nature of serious complications 
such as chronic atrial arrhythmia and PAH, in order to promote com-
pliance with further medical treatment.
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